146 related articles for article (PubMed ID: 6589560)
1. Prolonged methotrexate infusions in children with acute leukemia in relapse and in remission and with medulloblastoma. Pharmacokinetics, toxicity and clinical results.
Janka GE; Mack R; Helmig M; Haas RJ; Bidlingmaier F
Oncology; 1984; 41(4):225-32. PubMed ID: 6589560
[TBL] [Abstract][Full Text] [Related]
2. High-dose methotrexate as part of remission maintenance therapy for childhood acute lymphocytic leukemia: a Pediatric Oncology Group pilot study.
Frankel LS; Wang YM; Shuster J; Nitschke R; Doering EJ; Pullen J
J Clin Oncol; 1983 Dec; 1(12):804-9. PubMed ID: 6583318
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.
Evans WE; Hutson PR; Stewart CF; Cairnes DA; Bowman WP; Rivera G; Crom WR
Clin Pharmacol Ther; 1983 Mar; 33(3):301-7. PubMed ID: 6600662
[TBL] [Abstract][Full Text] [Related]
4. Transient acute hepatotoxicity of high-dose methotrexate therapy during childhood.
Weber BL; Tanyer G; Poplack DG; Reaman GH; Feusner JH; Miser JS; Bleyer WA
NCI Monogr; 1987; (5):207-12. PubMed ID: 3481038
[TBL] [Abstract][Full Text] [Related]
5. High-dose methotrexate in acute lymphocytic leukemia.
Freeman AI; Wang JJ; Sinks LF
Cancer Treat Rep; 1977 Jul; 61(4):727-31. PubMed ID: 267510
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and toxicity of frequent intermediate dose methotrexate infusions.
Parker RI; Forman EN; Krumm KF; Abeel MJ; Martin HF
Ther Drug Monit; 1986; 8(4):393-9. PubMed ID: 3469802
[TBL] [Abstract][Full Text] [Related]
7. Remission induction of meningeal leukemia with high-dose intravenous methotrexate.
Balis FM; Savitch JL; Bleyer WA; Reaman GH; Poplack DG
J Clin Oncol; 1985 Apr; 3(4):485-9. PubMed ID: 3856631
[TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.
Lange BJ; Blatt J; Sather HN; Meadows AT
Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385
[TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.
Wolfrom C; Hartmann R; Fengler R; Brühmüller S; Ingwersen A; Henze G
J Clin Oncol; 1993 May; 11(5):827-33. PubMed ID: 8487046
[TBL] [Abstract][Full Text] [Related]
10. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study.
Camitta B; Mahoney D; Leventhal B; Lauer SJ; Shuster JJ; Adair S; Civin C; Munoz L; Steuber P; Strother D
J Clin Oncol; 1994 Jul; 12(7):1383-9. PubMed ID: 8021728
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
[TBL] [Abstract][Full Text] [Related]
12. Disposition of intermediate-dose methotrexate in children with acute lymphocytic leukemia.
Evans WE; Stewart CF; Hutson PR; Cairnes DA; Bowman WP; Yee GC; Crom WR
Drug Intell Clin Pharm; 1982 Nov; 16(11):839-42. PubMed ID: 6959800
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate and asparaginase combination chemotherapy in refractory acute lymphoblastic leukemia of childhood.
Lobel JS; O'Brien RT; McIntosh S; Aspnes GT; Capizzi RL
Cancer; 1979 Mar; 43(3):1089-94. PubMed ID: 284840
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
15. [New aspects of the determination of blood methotrexate levels in leukemic children].
Schuler D; Borsi J; Koós R; Révész T; Kardos G; Somló P
Monatsschr Kinderheilkd; 1986 Oct; 134(10):765-8. PubMed ID: 3467178
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia.
Garré ML; Relling MV; Kalwinsky D; Dodge R; Crom WR; Abromowitch M; Pui CH; Evans WE
J Pediatr; 1987 Oct; 111(4):606-12. PubMed ID: 2958611
[TBL] [Abstract][Full Text] [Related]
17. Effect of hydration on methotrexate plasma concentrations in children with acute lymphocytic leukemia.
Christensen ML; Rivera GK; Crom WR; Hancock ML; Evans WE
J Clin Oncol; 1988 May; 6(5):797-801. PubMed ID: 3163362
[TBL] [Abstract][Full Text] [Related]
18. Sequential combination of methotrexate and L-asparaginase in the treatment of refractory acute leukemia.
Amadori S; Tribalto M; Pacilli L; De Laurentis C; Papa G; Mandelli F
Cancer Treat Rep; 1980; 64(8-9):939-42. PubMed ID: 6934851
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin's lymphoma.
Ettinger LJ; Chervinsky DS; Freeman AI; Creaven PJ
Cancer; 1982 Nov; 50(9):1676-82. PubMed ID: 6956429
[TBL] [Abstract][Full Text] [Related]
20. Effect of etoposide on the pharmacokinetics of methotrexate in vivo.
Paál K; Horváth J; Csáki C; Ferencz T; Schuler D; Borsi JD
Anticancer Drugs; 1998 Oct; 9(9):765-72. PubMed ID: 9840721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]